Around 42% of B-ALL cases that express MPO show evidence of t(9;22) translocation, are likely to express CD13 or CD15, and are associated with a chronic myeloid leukemia blast phase (CML-blast) rather than de novo ALL [20]. This evidence concerns the gene ANPEP and chronic myelogenous leukemia, BCR-ABL1 positive.